
In a recent study, increased rates of precocious puberty were observed during the COVID-19 pandemic compared to prior years.

In a recent study, increased rates of precocious puberty were observed during the COVID-19 pandemic compared to prior years.

In this Contemporary Pediatrics interview, James Wallace, MD, discusses increased trends in school avoidance and the negative effects associated with less days in the classroom.

Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.

Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.